|
Τίτλος – Title
|
The Interrelationship between Metabolic Syndrome and Polycystic Ovary Syndrome in Greek women.
A Retrospective Study
|
|
|
Συγγραφέας – Author
|
Giannoula Kyrkou1,3, Eftichios Trakakis2, Achilleas Attilakos1, Kleanthi Gourounti3, Katerina Lykeridou3 1Third Department of Pediatric, University of Athens “Attikon” Hospital, Athens, Greece 2Third Department of Obstetrics & Gynecological, University of Athens “Attikon” Hospital, Athens, Greece 3Midwifery Department, University of West Attica, Athens, Greece |
|
|
Παραπομπή – Citation
|
G. Kyrkou, E. Trakakis, A. Attilakos, K. Gourounti, K. Lykeridou : The Interrelationship between Metabolic Syndrome and Polycystic Ovary Syndrome in Greek women. A Retrospective Study, Rev. Clin. Pharmacol. Pharmacokinet. 33: 13-17 (2019)
|
|
|
Ημερομηνία Δημοσιευσης – Publication Date
|
20 Μαρτίου 2019 – 2019-03-20
|
|
|
Γλώσσα Πλήρους Κειμένου – Full Text Language
|
Αγγλικά – English
|
|
|
Λέξεις κλειδιά – Keywords
|
Polycystic Ovary Syndrome, prevalence, Metabolic Syndrome
|
|
|
Λοιποί Όροι – Other Terms
|
άρθρο επισκόπησης |
|
|
Περίληψη – Summary
|
Polycystic ovary syndrome is among the most common endocrine disorders of women in the reproductive age group. PCOS has been strongly associated with MS and insulin resistance, so there is an increased prevalence of MS in women with PCOS. PCOS and the MS appear to be interrelated and the PCOS-MS interrelationship is not restricted to Caucasian women with PCOS. In women with PCOS indicated differences in the prevalence of MS among people. The Aim of this study was to investigate the prevalence of MS in Greek women with PCOS. Method and material: In 230 Greek women, which have been diagnosed with PCOS according to the criteria of the Rotterdam ESHRE, aged from 12 to 44 years, correlation for the diagnosis of MS the abdominal circumference, the fasting glucose, the TG, the HDL-C, the systolic and the diastolic pressure, using criteria of IDF. The prevalence of MS of Greek women with PCOS is 10% (IDF criteria). Pathological variables in the MS to the general population with PCOS: abdominal circumference (>80cm) rate of 63%, HDL-C (<50mg/dl) 26,5%, TG (>150mg/dl) 10,4%, fasting glucose (>100mg/dl) 7,4%, diastolic blood pressure (>85mm/Hg) 6,1%, systolic blood pressure (130mm/HG) 4,3%. The prevalence of MS according to age: minimum age to 19 years 0%, 20 to 24 years 6,76%, 25 to 29 years 9,62%, 30 to 34 years 17,14% and 35 to maximum age 55,56%. The paphological variables of MS in all age groups have the primary finding of increased abdominal circumference and secondary finding the decreased levels of HDL-C, also a gradual increased observed in diastolic blood pressure and fasting glucose. In conclusion, women with PCOS have an increased risk of cardiovascular disorders and incidence of diabetes type 2, so the systematic information and the follow up will prevent future pathological situations. |
|
|
Αναφορές – References
|
1. Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181.
2. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. doi: 10.1186/1741-7015-8-41. 3. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–8. doi: 10.1210/jc.2005-0628. 4. Dokras A, Bochner M, Hollinrake E, Markham S, VanVoorhis B , Jagasia DH . Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106:131–7. doi: 10.1097/01.AOG.0000167408.30893.6b. 5. Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4797–802. doi: 10.1210/jc.2004-2217. 6. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril. 2011;96:1271–4. doi: 10.1016/j.fertnstert.2011.08.006. 7. Cheung LP, Ma RC, Lam PM, et al. (2008) Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 23:1431-143 8. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA (2006) Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS Eur J Endocrinol 154:141-145 9. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in with polycystic ovary syndrome. CLin Endocrinol Metab 2005; 90:1929-1935 10. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA (2003) Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 18:2289-2293 11. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S (2003) Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 61:29-37 12. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. (2005) MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 7:397-405 13. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. (2004) Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. C.Am Heart J 147:106-112 14. Third Report of the National Cholesterol Education Program (NCEP) 2002 Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421 15. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf, last accessed in August 2007 16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation.112:2735-52. 17. Carmina E, Napoli N, Longo R, Rini G, Lobo R. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5. doi: 10.1530/eje.1.02058. [PubMed] [Cross Ref] 18. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–35. doi: 10.1210/jc.2004-1045. [PubMed] [Cross Ref] 19. Ranasinha S, Joham AE, Norman RJ, Shaw JE, Zoungas S, Boyle J. et al. The association between Polycystic Ovary Syndrome (PCOS) and metabolic syndrome: a statistical modelling approach. Clin Endocrinol. 2015;83:879–87. doi: 10.1111/cen.12830. [PubMed] [Cross Ref] 20. The IDF consensus worldwide definition of the metabolic syndrome in children and adolescents http://www.idf.org/webdata/docs/Mets_definition_children.pdf accessed in 2007 21. Ferriman D, Gallwey JD (1961) Clinical assessment of body hairgrowth in women. J Clin Endocrinol Metab 21:1440–1447 22. Kauffman, R.P., Baker, T.E., Baker, V.M., DiMarino, P., Castracane, V.D., 2008. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. American Journal of Obstetrics and Gynecology. 198, 670.e1–670.e10 23. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2009 Mar;24(3):710-7 24. Marcondes JA, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol. 2007 Aug;51(6):972-9. 25. Sudhidra M, Bhattacharya SM (2008) Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res 34:62-66 26. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG (2008) Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 23:2352-2358 27. Panidis D, Macut D, Tziomalos K, et al. (2013) Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 78:586-592 |
|
|
Σχετικές Εργασίες – Relative Papers
|
Online ISSN 1011-6575
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση-Οδηγίες προς τους Συγγραφείς What is Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition-Instrunctions to Authors
Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση Articles Published in Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition
Συντακτικη Επιτροπή-Editorial Board
|
ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2019 – ANNUAL SUBSCRIPTION 2019
|
||
|
Γλώσσα Πλήρους Κειμένου – Full Text Language
|
Αγγλικά – English
|
|
|
Παραγγελία – Αγορά – Order – Buy
|
Ηλεκτρονική Μορφή: pdf (100 €) – Digital Type: pdf (100 €)
pharmakonpress[at]pharmakonpress[.]gr
|
|
|
Έντυπη Μορφή (100 € + έξοδα αποστολής) – Printed Type (100 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr
|
||